跳转至内容
Merck
所有图片(1)

Key Documents

P2698000

泼尼卡酯

European Pharmacopoeia (EP) Reference Standard

别名:

(11β)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)pregna-1,4-diene-3,20-dione

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C27H36O8
CAS号:
分子量:
488.57
EC號碼:
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

prednicarbate

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

InChI

1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3

InChI 密鑰

FNPXMHRZILFCKX-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Prednicarbate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

V Niemeier et al.
The Journal of dermatological treatment, 16(2), 95-101 (2005-07-16)
The treatment of atopic dermatitis still remains a challenge. Little research has been done on the issue of the extent to which patients correctly use prescribed topical preparations under everyday conditions. To investigate what quantity of topical preparations is applied
Aditya K Gupta et al.
Journal of cutaneous medicine and surgery, 8(4), 244-247 (2005-08-11)
Topical steroids have been a popular choice for treating various cutaneous disorders; however, the potential for significant local and systemic adverse events, like skin atrophy and hypothalamic-pituitary-adrenal (HPA) axis suppression, has limited their use. This article reviews the topical steroid
Kerstin Katzer et al.
European journal of dermatology : EJD, 20(1), 82-84 (2009-10-03)
The epidermal growth factor receptor (EGFR) inhibitor cetuximab is used to treat advanced stages of solid tumors. Acneiform skin eruptions, the most common side effects of cetuximab, stigmatize the patient in daily life and may lower compliance. As oral treatment
Aditya K Gupta et al.
Journal of drugs in dermatology : JDD, 3(5), 553-556 (2004-11-24)
Prednicarbate is a non-halogenated, double-ester derivative of prednisolone that has become of interest for the treatment of inflammatory skin diseases, for example atopic dermatitis. In the past, topical steroids have been a popular choice for treating these diseases; however, the
I Spika et al.
Skin pharmacology and applied skin physiology, 16(3), 143-150 (2003-04-05)
As compared to standard glucocorticoids (GC), prednicarbate (PC) is favorable in the treatment of eczema due to its high benefit/risk ratio. The remarkable anti-inflammatory effects of PC are in strong contrast to its reported low glucocorticoid receptor (GR) binding affinity.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门